Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
Iris de Weerdt
Department of Hematology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands / Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands
EHA Library. Kater A. Jun 15, 2019; 273672
Arnon Kater
Arnon Kater
Learning Objectives

Tadeusz Robak - Chair introduction

Chronic lymphocytic leukemia (CLL) is the most common forms of adult leukemia in the Western world, and is typically diagnosed at 70 years. This is an exciting era in CLL biology, particularly for its understanding, prognostic classification and novel treatment approaches. This educational session will review recent developments in the biology and treatment of CLL. In the first talk, Dr Philip J Law and Dr Richard S Houlston from the Institute of Cancer Research, Sutton (United Kingdom) will review the familial risks of CLL. They will discuss the genomewide association studies (GWAS) that identified the single nucleotide polymorphisms (SNPs) at 43 genetic regions influencing the risk of sporadic CLL. Therapeutic strategies are changing rapidly with the introduction of newer drugs, most of which are orally available, and which are more effective and better tolerated than previously-available therapies. Two of the leading agents now used in the treatment of CLL are ibrutinib and venetoclax. Although these newer agents have improved the prognosis of CLL, particularly in older patients and patients with high-risk genetics, especially thosewith del 17p/TP53 mutation and unmutated immunoglobulin variable region heavy chain (IGHV), resistant cases are sometimes observed and treatment is often discontinued due to disease progression. In the second lecture, Dr LA Sutton from the Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm (Sweden) will review the mechanism of resistance to novel antileukemic agents used inCLL. Finally, Dr Iris de Weerdt and Dr Arnon P Kater from the University of Amsterdam (The Netherlands) will review new treatment approaches, particularly combination therapies including chemotherapy-free regimens, in previously-untreated and refractory/relapsed patients with CLL in 2019. The results of recent trials clearly demonstrate improved progression-free survival, and sometimes overall survival, associated with the use of newtargeted drugs, as single agents or in combination with anti-CD20 monoclonal antibodies, compared with chemoimmunotherapy.

Learning goals of the article
• Get knowledge of the growing importance of molecular genetics providing evidence for inherited susceptibility to CLL and risk of sporadic disease.
• To understand the mechanisms of acquired clinical resistance in patients treated with novel targeted drugs, particular with ibrutinib, idelalisib, and venetoclax.
• To learn that many new combination therapies with targeted drugs, monoclonal anti-CD20 antibodies and chemotherapy will improve the outcome of the standard of care for CLL.

Learning goals of the presentation
After attending this lecture, the participant will be able to
• describe current and emerging chemofree therapies for frontline and relapsed CLL,
• select appropriate upfront therapy based upon patient and disease characteristics, and
• discuss treatment options, durations and sequence of treatments for both fit and less fit patients.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies